SCHEMBL6739265

SCHEMBL6739265

CCCNCCCN1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
SCN5A Q14524 2/20 0.46
HRH3 Q9Y5N1 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
PAOX Q6QHF9 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
KDM1A O60341 1/20 0.40
MBTD1 Q05BQ5 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8220855 0.98 HRH3 (0.50) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL13822725 0.91 ACE2 (0.48) SCN5ASMN1; SMN2ALDH1A1PAOXACE2
SCHEMBL5910693 0.89 HRH3 (0.57) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL21348139 0.88 ALDH1A1 (0.52) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL7446808 0.86 CARM1 (0.56) CARM1PRMT6PRMT8HRH3ALDH1A1
SCHEMBL17526224 0.86 HRH3 (0.55) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL5911217 0.86 HRH3 (0.62) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL17526233 0.86 HRH3 (0.55) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL21348177 0.86 HRH3 (0.52) CARM1PRMT6PRMT8SCN5AHRH3
SCHEMBL13655836 0.85 ACE2 (0.43) SMN1; SMN2ALDH1A1KDM4EPAOXACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149910-A1 CATALYST COMPOSITION MOMENTIVE PERFORMANCE MATERIALS INC. 2023-05-18 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-29 US disclosed
US-8992991-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-31 US disclosed
US-8992991-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-31 US disclosed
US-20120128782-A1 Multicomponent Degradable Cationic Polymers THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-24 US disclosed
US-20120128782-A1 Multicomponent Degradable Cationic Polymers THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-24 US disclosed
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-10 US disclosed
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-10 US disclosed
US-RE38415-E1 POLYMERIZATION CATALYSTS SUCH AS N-(3-AMINOPROPYL)PYRROLIDINE USED FOR COPOLYMERIZATION OR CONDENSATION POLYMERIZATION OF POLYURETHANES, POLYUREAURETHANE COPOLYMERS OR POLYUREAS BAYER AKTIENGESELLSCHAFT (DE) 2004-02-03 US disclosed
EP-0495249-B1 Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas BAYER AG (DE) 1994-07-27 EP disclosed
US-5134217-A Forming polyurethanes modified with chain extension agents for foams BAYER AKTIENGESELLSCHAFT (DE) 1992-07-28 US disclosed
EP-0495249-A1 Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas BAYER AG (DE) 1992-07-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 CARM1 4787/4885PRMT6 3542/4885PRMT8 4203/4885
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 CARM1 4787/4885PRMT6 3542/4885PRMT8 4203/4885
US-20120128782-A1 Multicomponent Degradable Cationic Polymers PEF1, FIBP, PARN CARM1 2255/4885PRMT6 1969/4885PRMT8 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.